Unknown

Dataset Information

0

Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic.


ABSTRACT: BACKGROUND:Cancer diagnostics and surgery have been disrupted by the response of healthcare services to the COVID-19 pandemic. Progression of cancers during delay will impact on patient long-term survival. METHODS:We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of three months and six months and periods of disruption of one year and two years. Using healthcare resource costing, we contextualise attributable lives saved and life-years gained from cancer surgery to equivalent volumes of COVID-19 hospitalisations. FINDINGS:Per year, 94,912 resections for major cancers result in 80,406 long-term survivors and 1,717,051 life years gained. Per-patient delay of three/six months would cause attributable death of 4,755/10,760 of these individuals with loss of 92,214/208,275 life-years. For cancer surgery, average life-years gained (LYGs) per patient are 18.1 under standard conditions and 17.1/15.9 with a delay of three/six months (an average loss of 0.97/2.19 LYG per patient). Taking into account units of healthcare resource (HCRU), surgery results on average per patient in 2.25 resource-adjusted life-years gained (RALYGs) under standard conditions and 2.12/1.97 RALYGs following delay of three/six months. For 94,912 hospital COVID-19 admissions, there are 482,022 LYGs requiring of 1,052,949 HCRUs. Hospitalisation of community-acquired COVID-19 patients yields on average per patient 5.08 LYG and 0.46 RALYGs. INTERPRETATION:Modest delays in surgery for cancer incur significant impact on survival. Delay of three/six months in surgery for incident cancers would mitigate 19%/43% of life-years gained by hospitalisation of an equivalent volume of admissions for community-acquired COVID-19. This rises to 26%/59% when considering resource-adjusted life-years gained. To avoid a downstream public health crisis of avoidable cancer deaths, cancer diagnostic and surgical pathways must be maintained at normal throughput, with rapid attention to any backlog already accrued.

SUBMITTER: Sud A 

PROVIDER: S-EPMC7237184 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic.

Sud A A   Jones M E ME   Broggio J J   Loveday C C   Torr B B   Garrett A A   Nicol D L DL   Jhanji S S   Boyce S A SA   Gronthoud F F   Ward P P   Handy J M JM   Yousaf N N   Larkin J J   Suh Y-E YE   Scott S S   Pharoah P D P PDP   Swanton C C   Abbosh C C   Williams M M   Lyratzopoulos G G   Houlston R R   Turnbull C C  

Annals of oncology : official journal of the European Society for Medical Oncology 20200519 8


<h4>Background</h4>Cancer diagnostics and surgery have been disrupted by the response of health care services to the coronavirus disease 2019 (COVID-19) pandemic. Progression of cancers during delay will impact on patients' long-term survival.<h4>Patients and methods</h4>We generated per-day hazard ratios of cancer progression from observational studies and applied these to age-specific, stage-specific cancer survival for England 2013-2017. We modelled per-patient delay of 3 and 6 months and per  ...[more]

Similar Datasets

| S-EPMC8013664 | biostudies-literature
| S-EPMC7501790 | biostudies-literature
| S-EPMC7430182 | biostudies-literature
| 2656898 | ecrin-mdr-crc
| S-EPMC9494405 | biostudies-literature
| 2364120 | ecrin-mdr-crc
| 2354636 | ecrin-mdr-crc
| S-EPMC10493828 | biostudies-literature
| S-EPMC10954826 | biostudies-literature